Livagen Peptide: Chromatin Remodeling, Liver Models, and Immune Cell Studies

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Livagen is a short peptide bioregulator with the amino acid sequence Lys-Glu-Asp-Ala (KEDA). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology. The peptide was created by analyzing amino acids from complex peptide preparations found in calf liver tissue.

Research on the bioregulatory peptide focuses on its ability to change chromatin structure at the epigenetic level. Studies show that the peptide affects gene expression through direct interactions with DNA and chromatin proteins. This makes it a useful tool for exploring age-related changes in cellular function.

Key Highlights

• Livagen activates silenced ribosomal genes and decondenses heterochromatin in aged lymphocyte cultures
• The peptide inhibits enkephalin-degrading enzymes without directly binding to opioid receptors
• Hepatocyte studies show Livagen restores protein synthesis rates and circadian rhythms in aged liver cells
• Research demonstrates modulation of lymphocyte markers and complement activation pathways

Livagen Molecular Specifications

Livagen’s molecular structure and properties allow for precise experimental design and protocol development. The peptide’s relatively small size facilitates cellular uptake in research models.

Property	Value
Amino Acid Sequence	H-Lys-Glu-Asp-Ala-OH
Molecular Formula	C₁₈H₃₁N₅O₉
Molecular Weight	461.5 g/mol
CAS Number	195875-84-4
PubChem CID	87919683

Chromatin Remodeling Research

Livagen’s main mechanism involves changing the structure of chromatin through a process known as de-heterochromatinization. This means activating tightly packed regions of DNA that are usually silent in terms of transcription.

Research published in studies with lymphocyte cultures shows that Livagen activates heterochromatinized regions in chromosomes. The peptide affects chromatin structure through several pathways that work together to improve DNA accessibility for transcription^[1].

Studies using 10 nm chromatin filaments showed that Livagen unfolds the nucleosomal core, releasing approximately 15% of core DNA. This structural change increases the temperature range where DNA melts, matching that of internucleosomal linker regions^[2].

The unfolding process makes previously inaccessible genetic sequences available for transcription machinery. This mechanism appears to reverse age-related chromatin condensation that silences genes over time.

Effects on Aged Lymphocytes

Research using cultured lymphocytes from individuals aged 75-88 years identified four distinct chromatin effects^[3]:

• Ribosomal gene activation through reactivation of nucleolus organizer regions
• Pericentromeric heterochromatin decondensation specifically in chromosomes 1, 9, and 16
• Total heterochromatin unrolling documented across the genome
• Gene release from facultative heterochromatin formed by age-related condensation of euchromatic regions

This gene release pattern suggests potential applications in aging research models.

Related Product: Buy Livagen Peptide for laboratory research use.

DNA Interaction Studies

Short peptides including Livagen can penetrate cell nuclei and interact directly with nucleosomes, histone proteins, and both single- and double-stranded DNA. Molecular modeling indicates that peptides with structures similar to Livagen bind selectively to specific DNA sequences^[4].

Promoter Binding Research

The tetrapeptide KEDA regulates gene expression through complementary interaction with gene promoter sequences. Research suggests this binding serves as a transcription regulatory signal that induces expression of specific genes and proteins^[4].

Key characteristics of Livagen’s DNA interaction include:

• Selective binding to specific DNA sequences in promoter regions
• Template-directed process for gene activation
• May represent an evolutionarily ancient signaling mechanism

The binding specificity allows researchers to investigate how short peptide sequences influence transcriptional regulation. This makes Livagen a tool for studying epigenetic mechanisms in laboratory models.

Opioid System Research

Livagen demonstrates activity within the endogenous opioid system through an indirect mechanism. Studies established that Livagen inhibits enkephalin-degrading enzymes in human serum with an IC₅₀ of 20 μM^[5].

The peptide proved more efficient than established peptidase inhibitors including puromycin, leupeptin, and D-PAM. This inhibition preserves endogenous enkephalin levels rather than activating receptors directly.

Enkephalinase Inhibition

Radioreceptor assays using labeled enkephalin derivatives confirmed that Livagen does not directly interact with mu- or delta-opioid receptors in brain membrane fractions. This finding distinguishes Livagen’s mechanism from direct receptor agonists^[5].

The preservation of endogenous enkephalin levels suggests applications in research models investigating opioid peptide metabolism. Livagen offers a tool for studying enzyme inhibition effects without receptor activation.

Research on mu and delta opioid receptors indicates these receptors play roles in mucosal barrier function when activated. Through enkephalin preservation, Livagen may influence vagal nerve signaling and alter levels of mucosal nitric oxide and prostaglandins in gastrointestinal research models.

Hepatocyte Research Models

Livagen demonstrates tissue-specific activity toward liver cells in multiple research contexts. Studies provide evidence for age-related effects on hepatocyte function and circadian rhythm restoration.

Protein Synthesis Studies

Research using hepatocyte cultures from aged rats showed that nanomolar concentrations of Livagen increased protein synthesis rates. The synthesis rates approached levels characteristic of young specimens^[5].

The tetrapeptide also restored disrupted intracellular circadian rhythms of biosynthesis that become impaired during aging. This chronobiological effect suggests applications in research on age-related metabolic changes.

Protein synthesis restoration occurred at very low concentrations, indicating high potency in hepatocyte models. The concentration-dependent response allows for dose-response characterization in laboratory settings.

Liver Tissue Applications

Studies on liver tissue explants from aged rats revealed that Livagen increased the explant area index by 15-16%. This measurement indicates a stimulating effect on liver tissue growth in culture systems^[7].

In models of experimental acute hepatitis, Livagen demonstrated multiple normalizing effects:

• Normalized bilirubin and cholesterol levels
• Restored ALT and AST enzyme markers to baseline ranges
• Stimulated tissue repair processes
• Reduced destructive dystrophic processes in liver stroma
• Normalized the number of cells containing glycogen (a marker of hepatocyte metabolic function)

The peptide influences digestive enzyme activity in age-dependent patterns. After two weeks of oral administration, enzyme activity decreased in young rats but increased in aged rats, with aged animals approaching activity levels seen in young controls^[6].

Third-Party Tested, USA-Made, 99% Purity

Lyophilized peptides for laboratory applications. 99% purity, 100% USA-Made.

Immune Cell Research

Through its chromatin-modifying effects on lymphocytes, Livagen influences immune cell function in laboratory models. Research demonstrates changes in cell surface markers and complement pathway activity.

Lymphocyte Marker Studies

In vitro incubation with leukocyte suspensions showed that Livagen modified lymphocyte populations^[7]:

• Increased lymphocytes carrying CD3+, CD4+, and CD8+ markers
• Decreased CD22+ cell populations
• Increased phagocytic activity of neutrophils in both healthy subjects and those with viral hepatitis A

Livagen’s effects on complement activation show dose-dependent modulation. The peptide inhibited complement activation via the classical pathway in samples from healthy subjects.

In samples from subjects with viral hepatitis A:

• Lower concentrations (40 μg/ml) activated the classical pathway
• Higher concentrations (60-160 μg/ml) inhibited the classical pathway
• The alternative pathway remained unaffected across all concentrations tested

These differential effects based on physiological state and concentration provide researchers with tools for investigating complement system regulation. The biphasic response pattern allows for modeling of concentration-dependent immune modulation.

Livagen Bioregulator Research Applications

Livagen’s multiple mechanisms of action provide researchers with applications across several areas of investigation. The table below outlines potential in vitro research applications based on published studies.

Research Area	Application
Epigenetics	Chromatin remodeling studies, gene expression analysis, heterochromatin decondensation models
Aging Research	Age-related gene silencing, circadian rhythm disruption, protein synthesis decline
Hepatology	Hepatocyte function, liver tissue culture, digestive enzyme regulation
Immunology	Lymphocyte marker expression, complement pathway modulation, neutrophil activity
Biochemistry	Peptidase inhibition, DNA-peptide interactions, enzyme kinetics

Conclusion

Livagen operates through interconnected pathways:

• Epigenetic chromatin remodeling and activation of silenced genes
• Direct DNA binding to promoter sequences
• Enkephalinase inhibition without direct receptor activation
• Tissue-specific effects on hepatocytes, lymphocytes, and cells of mesodermal origin

The peptide’s ability to modify chromatin structure makes it valuable for investigating age-related changes in gene expression. Applications span epigenetics, aging research, hepatology, and immunology.

For researchers investigating bioregulator peptides and chromatin-modifying compounds, sourcing considerations should include independent third-party testing verification. BioLongevity Labs provides research-grade Livagen with comprehensive analytical documentation including certificates of analysis from three independent certified laboratories, manufactured in USA GMP facilities for consistent quality in experimental protocols.

Livagen is intended for research use only. Not for human consumption.

---

---

References

1. Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, et al. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. Springer Science and Business Media LLC; 2002. https://doi.org/10.1023/a:1021924702103
2. Monaselidze J, Gorgoshidze M, Jokhadze T, Gaiozishvili M, Lezhava T. Influence of tetrapeptide on chromatin thermostability. Georgian Medical News. 2011;194:64–6.
3. Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News. 2006;133:111–5.
4. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. MDPI AG; 2021. https://doi.org/10.3390/molecules26227053
5. Kost N, Sokolov O, Gabaeva M, Zolotarev IA, Malinin V, Khavinson V. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii nauk Seriia biologicheskaia. 2003;4:427–9.
6. Timofeeva NM, Khavinson V, Malinin V, Nikitina A, Egorova VV. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Advances in Gerontology = Uspekhi Gerontologii. 2005;16:92–6.
7. Trofimova SV, Khavinson VKh, Trofimov AV, Dudkov AV, Attich K. Role of Short Peptides in Maintaining Liver Functional Activity. Cronicon; 2021.